Three years treatment with HDM allergen immunotherapy, omalizumab, or combination therapy in allergic asthma: clinical outcomes and biomarkers - PubMed
6 hours ago
- #allergen immunotherapy
- #allergic asthma
- #omalizumab
- The study compared 36-month outcomes of omalizumab, SCIT-HDM, and combination therapy in 79 patients with HDM-driven allergic asthma.
- All treatments reduced ICS use, with omalizumab and combination therapy showing greater reductions than SCIT-HDM and standard therapy.
- Combination therapy led to lower exacerbation rates and less oral corticosteroid use, and achieved the highest clinical remission rate (47%).
- Improvements in asthma control, lung function, and quality of life were observed across groups, with more consistent benefits for omalizumab and combination therapy.
- Biomarker changes indicated reduced type 2 inflammation, and no serious adverse events or systemic hypersensitivity reactions were reported.